AU2003288058A1 - Antibody- or neutrophil-mediated ozone generation - Google Patents

Antibody- or neutrophil-mediated ozone generation

Info

Publication number
AU2003288058A1
AU2003288058A1 AU2003288058A AU2003288058A AU2003288058A1 AU 2003288058 A1 AU2003288058 A1 AU 2003288058A1 AU 2003288058 A AU2003288058 A AU 2003288058A AU 2003288058 A AU2003288058 A AU 2003288058A AU 2003288058 A1 AU2003288058 A1 AU 2003288058A1
Authority
AU
Australia
Prior art keywords
neutrophil
mediated
antibody
ozone generation
ozone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003288058A
Other languages
English (en)
Other versions
AU2003288058A8 (en
Inventor
Richard A. Lerner
Paul Wentworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Scripps Research Institute
Original Assignee
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Scripps Research Institute filed Critical Novartis AG
Publication of AU2003288058A1 publication Critical patent/AU2003288058A1/en
Publication of AU2003288058A8 publication Critical patent/AU2003288058A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003288058A 2002-11-14 2003-11-13 Antibody- or neutrophil-mediated ozone generation Abandoned AU2003288058A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42624502P 2002-11-14 2002-11-14
US60/426,245 2002-11-14
PCT/EP2003/012710 WO2004044582A2 (en) 2002-11-14 2003-11-13 Antibody- or neutrophil-mediated ozone generation

Publications (2)

Publication Number Publication Date
AU2003288058A1 true AU2003288058A1 (en) 2004-06-03
AU2003288058A8 AU2003288058A8 (en) 2004-06-03

Family

ID=32313124

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003288058A Abandoned AU2003288058A1 (en) 2002-11-14 2003-11-13 Antibody- or neutrophil-mediated ozone generation

Country Status (8)

Country Link
US (1) US20060292076A1 (enExample)
EP (1) EP1563299A2 (enExample)
JP (1) JP2006506613A (enExample)
CN (1) CN100570365C (enExample)
AU (1) AU2003288058A1 (enExample)
BR (1) BR0315628A (enExample)
CA (1) CA2505923A1 (enExample)
WO (1) WO2004044582A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4998230B2 (ja) * 2007-11-26 2012-08-15 株式会社島津製作所 タンパク質試料中のメチオニン残基の酸化状態を解析する方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684521A (en) * 1982-12-08 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5162217A (en) * 1984-08-27 1992-11-10 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US6030611A (en) * 1984-08-27 2000-02-29 Bio-Technology General Corp. Therapeutic SOD compositions and uses thereof
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
DE3619436A1 (de) * 1986-06-10 1987-12-17 Bayer Ag Triaryl- und trihetarylmethanderivate als redoxindikatoren und deren verwendung
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US5599712A (en) * 1993-10-15 1997-02-04 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
US5647315A (en) * 1994-10-07 1997-07-15 Yamaha Hatsudoki Kabushiki Kaisha Lubricating arrangement for engine
JPH08249306A (ja) * 1995-03-09 1996-09-27 Sharp Corp データ駆動型情報処理装置
US6822070B2 (en) * 1996-03-11 2004-11-23 David Baltimore Truncated CRAF1 inhibits CD40 signaling
AU2394597A (en) * 1996-04-18 1997-11-07 Medical Research Council Oxidative metabolism in smooth muscle cells: methods and materials relating thereto
GB9621440D0 (en) * 1996-10-15 1996-12-04 Renold Plc A chain tensioner
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6040611A (en) * 1998-09-10 2000-03-21 Hughes Electonics Corporation Microelectromechanical device
EP1153010A1 (en) * 1999-02-08 2001-11-14 Checkpoint Genetics, Inc. $i(N)-SUBSTITUTED AMINO ACIDS, ANTIOXIDANT PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS USING SAME

Also Published As

Publication number Publication date
CN100570365C (zh) 2009-12-16
EP1563299A2 (en) 2005-08-17
WO2004044582A2 (en) 2004-05-27
BR0315628A (pt) 2005-08-23
JP2006506613A (ja) 2006-02-23
WO2004044582A3 (en) 2004-09-16
US20060292076A1 (en) 2006-12-28
CN1739028A (zh) 2006-02-22
AU2003288058A8 (en) 2004-06-03
CA2505923A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
AU2003205831A1 (en) Schematic generation
AU2003242768A1 (en) Optimised code generation
AU2003286894A1 (en) Hydrogen generator
AU2003282390A1 (en) Power toothbrush
AU2003209341A1 (en) Hydroelectric generator
GB0216482D0 (en) Power generation
AU2003252722A1 (en) Toothbrush
GB0402245D0 (en) Cross-reference generation
AU2003224302A1 (en) Cleaning produced water by combined ozonation and uv-oxidation
AU2003264124A1 (en) Horizontally assembled steam generator
GB0225855D0 (en) Power generation
AU2003215726A1 (en) Steam steriliser
GB2393321B (en) Plasma generation
AU2003229987A1 (en) Hydrogen generation
AU2003242450A1 (en) Power generation apparatus
AU2003297469A1 (en) Twin-headed toothbrush
HK1082038A (en) Antibody- or neutrophil-mediated ozone generation
AU2003288058A8 (en) Antibody- or neutrophil-mediated ozone generation
AU2002341610A1 (en) Ozone generator
AU2003300213A1 (en) Steam generator iron
AU2002258241A1 (en) Toothbrush
AU2002230214A1 (en) Ozone water producing device
AU2002249083A1 (en) Power generation system
AU2003236056A1 (en) Steam generator
AU2002347733A1 (en) Ozone generator

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase